HLN
Haleon plc
There isn't enough reported data to score HLN yet.
HLN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Unavailable | |
| Stable |
HLN's profitability is currently strong, and its balance sheet is stable. There isn't enough data to rate its revenue and cash flow.
HLN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 18x | $9.09 | — |
| Cheap | 20x | $4.96 | -45% |
| Fair | 26x | $6.41 | -30% |
| Expensive | 32x | $7.99 | -12% |
Historical ranges are pointers, not guarantees.
HLN's PE is 18x, but its earnings don't support one, so it isn't a reliable read right now.
HLN Forward outlook
There aren't enough analyst estimates for HLN to show an outlook.
HLN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | $0.25 | +19% |
| Q4 2024 | $0.21 | +40% |
| Q4 2023 | $0.15 | 0% |
HLN's earnings per share have climbed steadily: $0.25 over the past year, up 67% from the year before, and higher year over year every quarter since late 2025.
HLN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $14.7B | +99% |
| Q4 2024 | $7.4B | -0.4% |
| Q2 2024 | $7.6B | -0.8% |
| Q4 2023 | $7.4B | -49% |
| Q4 2022 | $14.4B | +336% |
HLN's revenue is growing: $14.7B last quarter, up 92% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 22% | +2 points |
| Q4 2024 | 19% | +2.2 points |
| Q2 2024 | 20% | -0.1 points |
| Q4 2023 | 15% | +0.7 points |
| Q2 2023 | 20% | N/A |
| Q4 2022 | 17% | N/A |
| Q4 2021 | 20% | N/A |
| Q2 2021 | 15% | N/A |
HLN's operating margin was 22% last quarter, up 2 points from the same quarter a year ago.
HLN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $3.1B | +79% |
| Q4 2024 | $1.7B | +4.5% |
| Q2 2024 | $1B | +21% |
| Q4 2023 | $1.6B | -30% |
| Q4 2022 | $2.3B | +$2.3B |
HLN's free cash flow has been positive every quarter since mid-2021: $7.5B over the past year, up 135% from the year before.
HLN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.6% | -149M shares |
| 1 year | -2.6% | -238M shares |
HLN has 9B diluted shares, down 2.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $200.9M |
| Q4 2024 | $267.4M |
| Q2 2024 | $421.7M |
| Q4 2021 | — |
| Q2 2021 | — |
HLN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 2.6x | Moderate |
| Q4 2024 | 3.1x | Elevated |
| Q2 2024 | 3.6x | Elevated |
| Q4 2023 | 3.7x | Elevated |
| Q4 2022 | 4.6x | High |
HLN's net debt is about 2.6 years of its operating earnings (EBITDA), down from 4.6 years a year ago.
HLN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.5 | Neutral |
| Stochastic | 28.9 | Neutral |
HLN's weekly RSI is 46 (neutral) and its Stochastic is 29 (neutral).
HLN PE vs Healthcare Sector
| Metric | HLN | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 29% below |
| PE % | 6 | 45 | 39 pts below |
HLN is trading at 18x earnings, a 29% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
HLN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.33 | 2.6% below |
| 20 week MA | $9.60 | 5.3% below |
| 50 week MA | $9.75 | 6.8% below |
| 100 week MA | $9.83 | 7.5% below |
| 200 week MA | $9.25 | 1.7% below |
HLN is in a downtrend: it's below all five of its weekly moving averages, and 1.7% below its 200-week average.
HLN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $7.41 | $8.00 | +8% |
| 2023 | $8.00 | $8.23 | +2.9% |
| 2024 | $8.23 | $9.64 | +17% |
| 2025 | $9.64 | $10.1 | +5.1% |
| 2026 YTD | $10.1 | $9.09 | -10% |
HLN has finished every year since 2022 higher, and it's down 10% so far in 2026.